Source: International Congress 2016 – Asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Guy Brusselle (Ghent, Belgium), Guy Brusselle, Jennifer McElhattan, Janice Canvin, Roland Buhl. Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials. Eur Respir J 2016; 48: Suppl. 60, 4107

Member's Comments

No comment yet.

Related content which might interest you: Reslizumab (RES) in patients (pts) with inadequately controlled asthma and elevated blood eosinophils (EOS): Analysis of two phase 3, placebo-controlled trials Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4 Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 SQ HDM SLIT-tablet is effective in patients not well-controlled in GINA treatment steps 2-4 Source: International Congress 2016 – Asthma management Year: 2016 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Asthma control, symptoms and exacerbations across treatment levels in patients with asthma Source: Annual Congress 2013 –Management of respiratory diseases in primary care Year: 2013 Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy Source: ERJ Open Res, 3 (3) 00004-2017; 10.1183/23120541.00004-2017 Year: 2017 Outcomes with omalizumab in Indian patients with allergic (IgE-mediated) asthma: Results at 16 and 28 weeks Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Safety of bronchial thermoplasty out to 5 years in patients with severe refractory asthma: Research in severe asthma (RISA) trial Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 LATE-BREAKING ABSTRACT: Benralizumab reduces exacerbations in severe, uncontrolled asthma: Results of the phase III CALIMA trial Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Real-life study on the aPpropriaTeness of treatment in moderate COPD patients (OPTIMO) Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 LATE-BREAKING ABSTRACT: Early identification of responders to reslizumab at 16 weeks using an algorithm derived from the pivotal clinical studies of severe eosinophilic asthma (SEA) patients Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities Year: 2016 Validation of the ’test of the adherence to inhalers’ (TAI) for asthma and COPD patients Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Omalizumab add-on therapy reduces exacerbations among responders: A pooled NNT analysis from 5 phase 3 studies Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021